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Background. Clinically, human immunodeficiency virus type 1 (HIV-1) pol sequences are used to evaluate for
drug resistance. These data can also be used to evaluate transmission networks and help describe factors associat-
ed with transmission risk.
Methods. HIV-1 pol sequences from participants at 5 sites in the CFAR Network of Integrated Clinical
Systems (CNICS) cohort from 2000–2009 were analyzed for genetic relatedness. Only the first available sequence
per participant was included. Inferred transmission networks (“clusters”) were defined as ≥2 sequences with
≤1.5% genetic distance. Clusters including ≥3 patients (“networks”) were evaluated for clinical and demographic
associations.
Results. Of 3697 sequences, 24% fell into inferred clusters: 155 clusters of 2 individuals (“dyads”), 54 clusters
that included 3–14 individuals (“networks”), and 1 large cluster that included 336 individuals across all study
sites. In multivariable analyses, factors associated with being in a cluster included not using antiretroviral (ARV)
drugs at time of sampling (P < .001), sequence collected after 2004 (P < .001), CD4 cell count >350 cells/mL
(P < .01), and viral load 10 000–100 000 copies/mL (P < .001) or >100 000 copies/mL (P < .001). In networks,
women were more likely to cluster with other women (P < .001), and African Americans with other African
Americans (P < .001).
Conclusions. Molecular epidemiology can be applied to study HIV transmission networks in geographically
and demographically diverse cohorts. Clustering was associated with lack of ARV use and higher viral load, imply-
ing transmission may be interrupted by earlier diagnosis and treatment. Observed female and African American
networks reinforce the importance of diagnosis and prevention efforts targeted by sex and race.
Comparative analysis of human immunodeficiency
virus type 1 (HIV-1) pol sequences can be used to
define transmission networks, or “clusters,” within a
population [1–7]. Across geographically distant com-
munities, identifying highly related clusters can evalu-
ate HIV transmission networks within and between
various populations. Such analyses could be particu-
larly useful for developing strategies to interfere with
HIV transmission among risk groups or among popu-
lations of interest, such as women and racial and
ethnic minorities.
Todate,mostHIVmolecular transmission studies have
focused on cohorts that are limited by geography [6],
HIV risk factor [2, 6, 8], recent infection [5, 7–11], or
epidemiologic linkage [7, 12]. This leaves open the ques-
tion of whether phylogenetic analysis could be useful to
identify HIV transmission networks in larger, more
diverse cohorts. Thus, we evaluated transmission net-
works within the CFAR Network of Integrated Clinical
Systems (CNICS) HIV cohort [13]. We sought to deter-
mine (1) whether transmission networks (clusters) can
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be identified in the CNICS cohort, consisting primarily of
chronically infected patients; (2) whether the density of sample
would be sufficient to study women and racial and ethnic mi-




CNICS is an observational HIV cohort at 8 US academic
centers [13]. Five CNICS sites contributed to this study: Univer-
sity of Washington (UW), University of California,
San Francisco (UCSF), Case Western Reserve University
(CWRU), University of North Carolina at Chapel Hill (UNC),
and Fenway Health/Harvard Medical School (FW). All partici-
pants who had an available HIV-1 pol nucleotide sequence were
included. For those with multiple sequences, the first sequence
was selected. Demographic and clinical data at time of sampling
included age, sex, self-reported race and ethnicity, self-reported
HIV risk factors, antiretroviral (ARV) use and ARV exposure
history, CNICS site, year, CD4 cell count, and viral load. Resis-
tance associated mutations in protease and reverse transcriptase
were evaluated based on International AIDS Society (IAS-USA)
definitions [14].
Cluster Analysis
We evaluated sequence relatedness using pairwise Tamura-Nei
93 (TN93) distances [15]. The TN93 distance corrects for sub-
stitution biases and unequal base composition in HIV [16] and
is a biologically realistic model that permits rapid comparisons
of 104–105 aligned sequences. Bulk pol sequences often contain
mixed nucleotide bases [17], representing within-host poly-
morphisms, and 87% of our sequences contained ≥1 mixed
base. We resolved mixed bases using a “partially derived” ap-
proach to maximize the number of nucleotide matches (see
Supplementary Methods). To define clustering, a group of se-
quences formed a cluster at a given threshold (D), if and only if
each sequence in the group had TN93 distance of D or less to
at least 1 other sequence in the group. As an example, if for
sequences A, B, and C, (A, B)≤ 1.5%, (A, C)≤ 1.5%, and
(B, C) > 1.5%, then the 3 sequences are in a cluster at D≤ 1.5%.
The D ≤ 1.5% genetic distance cutoff was selected based on
the following: (1) the expected genetic distance for genetically
unrelated sequences in the United States epidemic is >5% [18];
(2) 1.5% demarcated the 0.014 percentile of the TN93 distri-
bution, making it very unlikely for a pair of randomly selected
sequences to demonstrate <1.5% genetic distance from each
other; and (3) 1.5% is the standard used by others in the field
[3, 5, 19].
To ascertain that the largest cluster (cluster 3, comprising
336 individuals) was composed of related sequences, and not
the result of “chaining” the links (whereby 2 individuals in a
cluster are linked through several intermediaries but are them-
selves as distant as any 2 random sequences), we performed 2
checks. First, we computed the distribution of all pairwise dis-
tances in cluster 3 and compared it to the overall distribution
from the entire data set. Second, we drew 100 random subsets
of 336 sequences from the entire data set, computed all the
pairwise distances between pairs of sequences in each random
data set, evaluated the probability that a pairwise distance
from cluster 3 was greater than a pairwise distance from a
random cluster, and averaged this quantity over 100 random
clusters. We also evaluated the overlap between the tails of the
empirical pairwise TN93 distance distribution from cluster 3,
and the corresponding distribution from the random subset.
Univariate analyses (χ2) and multivariable logistic regres-
sion models were applied to determine associations between
variables and clustering. Groups analyzed included (1) all pa-
tients and (2) clustering versus nonclustering patients. For the
evaluation of resistance prevalence, we also included compari-
sons of patients who were ARV naive versus ARV experienced
and clustering ARV naive versus nonclustering ARV naive.
Spearman’s rank test for correlation was used to evaluate asso-
ciations between variables.
A subgroup analysis evaluated demographic characteristics
of the population that fell into larger clusters of ≥3 sequences
(termed “networks”), allowing for the identification of a pre-
dominant racial or sex characteristic of the cluster. For
example, if >50% of the members were female, the cluster was
defined as a “female network.” Then the proportion of females
who were in female networks was compared with the propor-
tion of females who were not in female networks using Fisher’s
exact test. The same method was used to evaluate associations
by race or ethnicity. To further confirm observed network as-
sociations by race and sex, we randomly permuted sex or race
labels among subjects found in defined networks and evaluated
the proportion of subjects expected to be in those networks if
association was random. This procedure was repeated 1000
times to derive the expected proportions and P values.
RESULTS
Study Population
All participants who had ≥1 HIV-1 pol sequence available
were evaluated: 1165 from UCSF, 1115 from UW, 666 from
CWRU, 512 from UNC, and 244 from FW. Of 3640 sequences
collected between 2000 and 2009, 5 contained errors and were
treated as missing, but an additional 62 sequences from 1999
and 3 sequences from 2010 were available and were included,
resulting in 3697 total sequences for the cluster analyses
(Table 1). Approximately 98% of sequences were subtype
B. The study population was 16% female, 33% African
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American, and 13% Hispanic (although there was a 40% non-
response rate for the Hispanic ethnicity variable). Self-report-
ed HIV risk factors included 50% men who have sex with
men (MSM), 23% heterosexual, 10% intravenous drug use
(IDU), and 10% both MSM and IDU risk factor (MSM/IDU).
At the time the sequence was generated, 41% were ARV naive
and 55% were experienced (4% unknown). Treatment experi-
enced patients may have been on or off therapy when the se-
quence was generated. During the study period, there was an
increase in the total number of sequences over time (mean
sequences per year, 190 for 2000–2003 vs 469 for 2004–2009)
and an increase in the proportion of ARV-naive participants
(mean, 15% in 2000–2003 vs 49% in 2004–2009).
Cluster Prevalence
The overall mean distribution of pairwise TN93 distances was
5.6% (median, 5.3%; interquartile range, 4.6%–6.3%; Supple-
mentary Figure 1). Of the 3697 sequences, 885 (24%) fell into
clusters at a genetic distance of ≤1.5%, resulting in 209 clus-
ters ranging in size from 2 to 14 individuals, plus 1 outlier
cluster, which encompassed 336 individuals (Figure 1).
Variables Associated With Clustering
In univariate analysis, individuals whose sequences clustered
were more likely to be younger (P = .02), ARV naive
Table 1. Demographic Characteristics
Patients, No. (%)
Characteristic All In a Cluster Not in a Cluster
All 3697 885 (24) 2812 (76)
Sex
Female 606 136 (22) 470 (78)
Male 3030 735 (24) 2295 (76)
Unknown 61 14 (23) 47 (77)
Race
Black 1216 273 (22) 943 (78)
White 1855 457 (25) 1398 (75)
Asian/PI 91 25 (27) 66 (73)
Other 232 50 (22) 182 (78)
Unknown 303 80 (26) 223 (74)
Ethnicity
Hispanic 468 126 (27) 342 (73)
Non-Hispanic 1499 341 (23) 1158 (77)
Unknown 1730 418 (24) 1312 (76)
Age, yearsa
≤40 1919 496 (26) 1423 (74)
>40 1656 373 (23) 1283 (77)
Unknown 122 16 (13) 106 (87)
HIV risk factor
MSM 1862 435 (23) 1427 (77)
Heterosexual 837 190 (23) 647 (77)
IDU 356 88 (25) 268 (75)
MSM/IDU 384 111 (29) 273 (71)
Unknown/other 258 61 (24) 197 (76)
CNICS siteb
UCSF 1161 331 (29) 830 (71)
UW 1114 249 (22) 865 (78)
CWRU 666 189 (28) 477 (72)
UNC 512 84 (16) 428 (84)
FW 244 32 (13) 212 (87)
Yearb
2000–2001 260 33 (13) 227 (87)
2002–2003 497 80 (16) 417 (84)
2004–2005 900 243 (27) 657 (73)
2006–2007 1190 308 (26) 882 (74)
2008–2009 723 210 (29) 513 (71)
Unknown/other 127 11 (8) 116 (92)
ARV historyb
Naive 1528 470 (31) 1058 (69)
Exposed 2047 399 (19) 1648 (81)
Unknown 122 16 (13) 106 (87)
ARV statusb
On ARV 1272 182 (14) 1090 (86)
Off ARV 2303 687 (30) 1616 (70)
Unknown 122 16 (13) 106 (87)
Viral load, copies/mLb
<10 000 1006 170 (17) 836 (83)
10 000–100 000 1382 361 (26) 1021 (74)
Table 1 continued.
Patients, No. (%)
Characteristic All In a Cluster Not in a Cluster
>100 000 844 250 (30) 594 (70)
Unknown 465 104 (22) 361 (78)
CD4 cell count, cells/mLc
<50 519 107 (21) 411 (79)
50–200 885 208 (24) 675 (76)
201–350 874 217 (25) 657 (75)
>350 1297 337 (26) 958 (74)
Unknown 122 16 (13) 111 (87)
Resistanceb
Yes 2004 371 (19) 1633 (81)
No 1693 514 (30) 1179 (70)
Abbreviations: ARV, antiretroviral; CNICS, CFAR Network of Integrated
Clinical Systems; CWRU, Case Western Reserve University; FW, Harvard/
Fenway; HIV, human immunodeficiency virus; IDU, intravenous drug use;
MSM, men who have sex with men; PI, Pacific Islander; UCSF, University of
California, San Francisco; UNC, University of North Carolina, UW, University
of Washington.
Univariate comparisons of cluster versus noncluster:
a P < .05.
b P < .001.
c Marginal association (P < .1).
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(P < .001), sampled after 2004 (P < .01), had higher viral loads
(P < .001), and were marginally more likely to have higher
CD4 cell counts (P = .09) than those who did not cluster.
Cluster patients were less likely to be from FW and UNC and
less likely to be receiving ARV therapy (P < .001) and to have
ARV resistance–associated mutations (P < .001; Table 1).
As expected, the viral load variable was significantly corre-
lated with CD4 cell counts (P < .001) and ARV use (P < .001).
The “ARV exposed” and “on ARV” variables were also highly
correlated (P < .001). Because those definitions overlapped,
only “on ARV” was included in the multivariate analysis. In
multivariate analysis (Table 2), later year of sampling, not cur-
rently receiving ARV therapy, higher viral load, and higher
CD4 cell counts remained independently associated with clus-
tering. Age ≤40 years and the MSM/IDU risk factor were
marginally associated with clustering (P = .09 and .06). Partici-
pants from the FW and UNC sites were less likely to fall into
clusters than participants from the other sites (P < .01), proba-
bly owing to fewer participants (lower sampling density) at
those sites. There was no difference in proportion clustering
by sex, race, or ethnicity.
Table 2. Multivariable Analysis for Likelihood of Clustering
Variable
Likelihood of Clustering,
OR (95% CI) P
Sex
Male … …
Female 1.1 (.8–1.6) .4
Race
Black … …
White 0.9 (.7–1.1) .33
Ethnicity
Hispanic 1.1 (.6–1.7) .7
Non-Hispanic
Age, years
≤40 1.2 (.9–1.4) .09
>40 … …
HIV risk factors (vs MSM)
MSM … …
Heterosexual 1.0 (.7–1.3) .8
IDU 1.1 (.8–1.6) .5
MSM/IDU 1.3 (1–1.7) .06
CNICS site (vs UCSF)
UCSF … …
UW 1.0 (.6–1.7) .9
CWRU 1.2 (.8–2.3) .3
UNC 0.6 (.4–.9) .01
FW 0.5 (.3–.8) .005
Year (vs 2000–2001)
2000–2001 … …
2002–2003 1.0 (.6–1.8) .9
2004–2005 2.0 (1.2–3.2) .009
2006–2007 1.6 (.9–2.6) .08
2008–2009 1.7 (1.0–2.9) .04
ARV status … …
On ARV
Off ARV 1.9 (1.5–2.4) <.0001
Viral load, copies/mL (vs <10 000)
<10 000 … …
10–100 000 1.6 (1.2–2.0) .0002
>100 000 2.0 (1.5–2.6) <.0001
CD4 cell count, cells/mL (vs <50)
<50 … …
50–200 1.1 (.9–1.8) .1
201–350 1.2 (1.0–1.8) .07
>350 1.5 (1.1–2.1) .006
Multivariable analysis included sex, race, ethnicity, age, HIV risk factors,
ARV status, CNICS site, categorical CD4 cell count and viral load,
and year of sampling. Boldface P values denote statistically significant
variables.
Abbreviations: ARV, antiretroviral; CNICS, CFAR Network of Integrated
Clinical Systems; CI, confidence interval; CWRU, Case Western Reserve
University; FW, Harvard/Fenway; HIV, human immunodeficiency virus; IDU,
intravenous drug use; MSM, men who have sex with men; OR, odds ratio;
UCSF, University of California, San Francisco; UNC, University of North
Carolina, UW, University of Washington.
Figure 1. Cluster overview with pictorial representation of all patients
who clustered at ≤1.5%. Each cluster patient (n = 885) is represented as
a colored dot with lines connecting phylogenetically linked sequences.
Black line connections represent genetic distances of <0.05%; dark gray
lines, 0.5%–1%; and light gray lines, 1%–1.5%. Sequences in cluster 3
can be seen in the center of the figure. Red dots represent patients from
the University of California, San Francisco; green, the University of Wash-
ington; blue, Harvard/Fenway; purple, Case Western Reserve University;
and orange, the University of North Carolina.
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Cluster Size and Clustering Across Sites
Of the 210 clusters, 155 (74%) included 2 participants
(“dyads”), 54 clusters included 3–14 individuals (“networks”;
n = 239), and 1 cluster (“cluster 3″) had 336 persons (Figure 2).
The majority of clusters were confined within geographic loca-
tions: only 22 of 210 clusters (and 9 of 54 networks) crossed 2
sites, and only cluster 3 spanned all sites.
Cluster 3 contained 336 individuals and arose from 7 se-
quences at the ≤0.5% genetic distance threshold, 65 at ≤1%, and
336 at ≤1.5%. Mean pairwise distance within the cluster was
0.032, significantly lower than expected by chance (P < .01; Sup-
plementary Figure 2). Comparison of the mean distance
between pairs of cluster 3 sequences and those of 100 random
subsets of 336 sequences found that the mean value from the
random subset was greater than that of cluster 3, highlighting
the close distance between cluster 3 sequences (Supplementary
Figure 3). Further, an evaluation of the tails of pairwise distance
distributions for cluster 3 and those estimated from the random
subsets found that the overlap was small (average 6.4%), again
supporting the unusual relatedness of sequences in this cluster.
Cluster 3 included sequences from all study sites, but partici-
pants were more likely to be from CWRU or UCSF and less
likely to be from UW or FW (P < .001). Cluster 3 patients were
more likely to be African American (P = .014), be >40 years old
(P < .001), have IDU as their HIV risk factors (P = .04), be ARV
experienced (P = .04) and have higher viral load (P = .002)
(Supplementary Table 1). These associations may represent
characteristics specific for this network, because they contrast
with the findings from the overall cohort, in which clustering
was associated with ARV-naive status and younger age.
Networks by Sex and Race
To investigate clustering by demographic group, networks were
investigated in a subgroup analysis, representing 43 females,
194 males, and 2 of unknown sex and 58 blacks, 46 Hispanics,
and 4 of unknown race. There were 9 majority-female net-
works, 16 “racial/ethnic minority” networks (14 majority
African American, 2 equally mixed black/Hispanic), and 1 ma-
jority-Hispanic network. Of the 43 women, 79% identified their
HIV risk factor as heterosexual contact, and 36 (84.3%) fell into
majority-female networks (P < .001; Figure 3A). Similarly,
African Americans were more likely to cluster with other
African Americans: 77% were in majority-black networks, and
84.5% were in black and/or Hispanic networks (P < .001;
Figure 3B). Based on 1000 replicates of a permutations test, the
observed ratios for clustering for females and racial or ethnic
minorities (83.7% for women, 84.5% for minorities) were signif-
icantly higher than the ratios expected by chance (15% and
32% respectively; P < .001). Although only 1 cluster included
>50% Hispanics (all from UW), Hispanic participants were also
more likely to cluster with African Americans; as a result, 58%
of Hispanics were in “minority” networks.
Resistance
Resistance prevalence was relatively high given that we defined
resistance as the presence of any IAS-USA major mutation,
Figure 2. Map of cohort population, percentage of clustering by site, and proportion of cluster patients in “dyads” (clusters of 2 patients), “networks”
(clusters of >2 patients), or in “cluster 3″ (a unique cluster that spanned all sites and included 9% of cluster sequences).
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but sequences that clustered were less likely to have resistance
compared to sequences that did not cluster (42% vs 58%;
P < .001; Table 1 and Supplementary Table 2A). As expected,
ARV-naive participants were less likely to have resistance mu-
tations than those who were ARV-experienced (37% vs 66%;
P < .001). Because ARV-naive participants were independently
more likely to cluster than the ARV-experienced group, this
may explain in part the lower prevalence of resistance among
those who clustered. When we analyzed only the ARV-naive
population, there was no difference in the prevalence of resis-
tance among those who clustered and those who did not (36%
vs 38%; P = .4), providing further evidence that viral evolution
associated with the development of drug resistance was not
associated with clustering (Supplementary Table 2B).
DISCUSSION
Traditional epidemiologic techniques for identifying and in-
terrupting HIV transmission networks are limited by individ-
ual recall and delays between infection and diagnosis. This is
underscored by a number of studies that have shown discord-
ance between patient-reported epidemiologic and phylogenetic
linkage [7, 19–21]. Although it is important to note that phy-
logenetic analysis is not an appropriate tool to identify direct
transmissions [22], it may provide accurate information on
transmission networks. This study used phylogenetic tech-
niques to investigate transmission networks in the United
States by including all available CNICS sequences without lim-
itation by stage of HIV infection, use of ARVs, demographics,
or geographic location.
Because previous studies using phylogenetic analysis have
assessed HIV transmission more narrowly by focusing on early
stages of infection [3, 6, 9, 11], specific risk groups [23, 24],
drug resistance [5,11,25,26],movement across regions [2, 27, 28],
and distribution of HIV-1 subtypes [4, 27, 29], our first aim
was to evaluate if inclusion of a broader population would
provide sufficient sample density to identify networks. We
found that the inclusion of chronically infected patients from
geographically distant sites across the United States demon-
strated a high degree of clustering (24% clustered with at least
Figure 3. Analysis of networks. Clusters containing ≥3 patients were defined by the predominant demographic characteristic of patients in that
network. For example, a network was defined as “female” if >50% of the patients in the network were female. A, Among women, 36 of 43 (84%)
clustered with other women. B, Among blacks, 45 of 58 (78%) clustered with other blacks.
1140 • CID 2012:55 (15 October) • HIV/AIDS
1 other person). The majority of these clusters were contained
within each site, providing evidence that identified networks
were likely true epidemiologic networks.
Our inferred transmission networks did not greatly overlap
across racial and ethnic boundaries, a finding also observed in
smaller studies of black men [30, 31] and a recent study of Los
Angeles County Service Planning Areas [32]. Interestingly, our
study also found networking by sex, with women much more
likely to fall into transmission networks with other women.
Although women represent 25% of the US epidemic [33], we
are not aware of any other large study of female transmission
networks using molecular epidemiology. In this retrospective
study we cannot determine specific epidemiologic relation-
ships between these women, but we propose 2 hypotheses: (1)
because most of the women self-identified as heterosexual, this
finding may point to a significant underdiagnosis of HIV in-
fection in men who have sex with women, and (2) these
clusters may represent female social networks with shared
risk. If so, this supports the possibility that HIV testing
focused on the social networks of HIV-positive women could
be effective in finding other undiagnosed HIV-infected
women [34, 35].
Clustering was associated with lack of ARV use, higher viral
load, and higher CD4 cell counts; factors also observed among
persons with newly acquired HIV infection. Higher CD4 cell
counts are also associated with ARV therapy, however ARV-
exposed patients were less, not more, likely to cluster. Thus, a
more likely explanation for higher CD4 cell counts in the
cluster group is that these participants were earlier in their
course of infection or had ARV therapy deferred based on
CD4 cell count guidelines [36, 37]. These associations are
similar to findings in other reports of HIV transmission
among recently infected individuals and those with higher
viral loads [3, 9, 38], and are consistent with other molecular
epidemiology studies that demonstrated phylogenetic cluster-
ing in both ARV-naive and experienced patients [39, 40]. To-
gether, these data add to the growing body of evidence that
early treatment may have a considerable impact on the spread
of the HIV epidemic [41, 42].
Cluster 3 was a significant outlier in size from the rest of
the observed clusters, encompassing 38% of all sequences that
clustered and 9% of sequences overall, and was overrepresent-
ed among MSM and IDU risk factors. Such a large cluster
raises questions that the cluster represents overlap of loosely
related smaller clusters. However, analysis of maximal distanc-
es within cluster 3 showed that its sequences were closely
related (Supplementary Figure 2) and that the chances of such
a cluster occurring by chance were quite low (Supplementary
Figure 3).
Although the results of the study were robust, some limita-
tions remain. It should be stressed again that we inferred
linkage based on genetic relatedness, which does not defini-
tively determine epidemiologic linkage or imply direct trans-
mission. However, the findings of clustering by demographic
and clinical factors provide substantial evidence that the phy-
logenetically inferred networks are probably true epidemiolog-
ic networks. We found that ARV use and viral load were
significantly associated with clustering, which fits with expec-
tations of transmission risks. However, certain clinical vari-
ables (ARV use, viral load, CD4 cell count) are highly
correlated, which may influence the power to see independent
effects, so there may have been other associations that we did
not have power to detect.
Including ARV-experienced participants may raise concerns
about falsely interpreting clustering secondary to drug resistant
mutations; however, measures of genetic distance removed the
codons associated with amino acid changes owing to resis-
tance [7, 43]. Similarly, including chronically infected individ-
uals may raise questions about viral evolution between time of
transmission and generation of the sequence [44]. However,
unlike other HIV genes (eg, env) pol evolves relatively slowly
(<1.5% over 5 years) [18].
Selection bias may arise from studying patients who under-
went genotyping and excluding those who did not; however,
whereas differences are possible (eg, patients who underwent
genotyping may have had higher viral loads than those who
did not undergo genotyping), it is unclear how they would
specifically affect the validity of inferred transmission net-
works. Self-reporting of HIV risk factors and ethnicity may
have also introduced some bias. For example, the cohort had a
high number of nonresponses for Hispanic ethnicity, so there
were probably more Hispanic patients in our networks than
were identified. Finally, the female and African American net-
works were small, making conclusions preliminary.
To our knowledge, this the first study to use molecular epi-
demiology to identify transmission networks in such a diverse
population, across such a wide geographic distribution, and
without limitations by stage of infection or ARV status. The
relatively high degree of clustering, and the fact that clusters
could be identified for demographic groups, confirms that,
even in large and diverse populations, relatedness of HIV-1
pol sequences can be used within and across communities to
assess variables associated with transmission networks. These
observations may also be important for public health interven-
tions, which could use assessments of transmission networks
to identify risks for expanding epidemics and target effective
public health responses.
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Supplementary materials are available at Clinical Infectious Diseases online
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